Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

NCT04090229 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.

NCT NCT04090229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04090229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
Lead sponsor
ASLAN Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 9, 2019
Completion date
December 3, 2021
Enrollment
52 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis